Press Release
No. 5/2013

Zealand informs of new scientific presentations on Lyxumia® (lixisenatide) and on proprietary GLP-1-gastrin dual agonist at the EASD 49th Annual Meeting

– On Lyxumia®, sub-analyses of data from the Phase III GetGoal program to be presented, including an analysis showing that the therapeutic efficacy of Lyxumia® added to basal insulin is greater when fasting blood-sugar levels are well-controlled

– Zealand to present new preclinical data on beta-cell mass expansion and survival from treatment with ZP3022, a GLP-1-gastrin dual acting receptor agonist

Copenhagen, 20 September, 2013 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") informs that new sub-analyses of data relating to Lyxumia® (lixisenatide) and new preclinical data relating to ZP3022, a compound from Zealand's proprietary GLP-1-gastrin dual acting receptor agonist program for the potential treatment of diabetes, will be presented at the European Association for the Study of Diabetes (EASD) 49th Annual Meeting on 23 – 27 September 2013 in Barcelona, Spain. Lyxumia® (lixisenatide), discovered by Zealand and licensed globally to Sanofi, is the first once-daily prandial GLP-1 receptor agonist marketed for the treatment of adults with type 2 diabetes.

Lyxumia® Phase III GetGoal clinical trial program sub-analyses
Lixisenatide has a predominant post-prandial glucose (PPG)-lowering effect, which complements the effect of basal insulin on fasting plasma glucose (FPG). Analyses from the extensive Phase III GetGoal clinical program examine efficacy and safety in specific patient populations, including those with controlled FPG and those with advanced type 2 diabetes:

"Therapeutic efficacy of lixisenatide added to basal insulin is greater when FPG is well-controlled" – ORAL PRESENTATION

When:	Tuesday September 24, 12:00 – 12:15 CET
Presenter:	J. Vidal, Endocrinology and Nutrition, University of Barcelona, Spain
Location:	Bernard Hall (Abs 006-EASD)

"*Efficacy of lixisenatide in patients with different levels of beta-cell function as assessed by C-peptide/glucose ratio*" – *POSTER PRESENTATION*

When: Wednesday September 25, 12:30 – 13:30 CET
Poster Author: J.J. Meier, Department of Medicine I, St.Josef-Hospital, Bochum, Germany
Location: Poster Hall, Event C – PS 069 (Abs 896-EASD)

New preclinical data on ZP3022, a GLP-1-gastrin dual agonist

At the meeting, Zealand will present new pre-clinical data on ZP3022, a compound from its own proprietary GLP-1-gastrin dual acting receptor agonist program for the potential treatment of diabetes.

"β-cell mass expansion and survival" – POSTER PRESENTATION

When: Thursday, September 26, 13.45 – 14.45 CET
Presenter: Jolanta Skarbaliene, Scientist, Ph.D. student, Zealand Pharma A/S
Location: Poster Hall, PS 030

***

For further information, please contact:
David H. Solomon, President and Chief Executive Officer
Tel: +45 2220 6300

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications
Tel: +45 5060 3689, email: hlh@zealandpharma.com

About Zealand

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company's focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia®) is approved in Europe and Japan and under regulatory review in a number of other countries globally. In the U.S., an NDA is planned to be submitted in 2015, after completion of the ELIXA CV outcome study.

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: www.zealandpharma.com.
@ZealandPharma